CMBA
SPRY icon

C.M. Bidwell & Associates’s ARS Pharmaceuticals SPRY Stock Holding History

C.M. Bidwell & Associates’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-48
Closed -$491 – 524
2024
Q1 		$491 Buy
48
+20
+71% +$149 ﹤0.01% 447
2023
Q4 		$153 Buy
+28
New +$123 ﹤0.01% 482

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

C.M. Bidwell & Associates's SPRY Position: Q2 2024 in Review

C.M. Bidwell & Associates sold out of ARS Pharmaceuticals (SPRY) in Q2 2024, closing a stake of 48 shares — an estimated $491 sold.

C.M. Bidwell & Associates first reported a position in SPRY in Q4 2023 and held it in 2 quarters. The position peaked at $491 in Q1 2024. 115 funds tracked by Wall St. Rank hold SPRY as of Q2 2024.

  • C.M. Bidwell & Associates reported no remaining ARS Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 48 ARS Pharmaceuticals shares in Q2 2024, an estimated $491.
  • C.M. Bidwell & Associates first reported a position in ARS Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • C.M. Bidwell & Associates's ARS Pharmaceuticals position peaked at $491 in Q1 2024.
  • 115 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2024.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2024, filed 13 Aug 2024.